

**FOR IMMEDIATE RELEASE**

Company Name Kyowa Kirin Co., Ltd.  
Representative Masashi Miyamoto, President and CEO  
(Code No. 4151, First Section of TSE)  
Inquiries Satoko Yoshida, Director,  
Corporate Communications Department  
Media Contact: +81-3-5205-7205  
Investor Contact: +81-3-5205-7206

## Matters Concerning Controlling Shareholders

**Tokyo, Japan, March 31, 2022** - Kyowa Kirin Co., Ltd. (hereinafter, "Kyowa Kirin") hereby provides information on "matters concerning controlling shareholders" with regard to its parent company Kirin Holdings Company, Limited. Details are as follows:

1. Names of the parent company, controlling shareholders (excluding parent company) and other associated companies and their parent companies.

(As of December 31, 2021)

Business name	Relationship	Ownership of voting rights (%)			Stock exchanges on which shares are listed
		Direct	Indirect	Total	
Kirin Holdings Company, Limited	Parent company	53.80	--	53.80	- Tokyo Stock Exchange, Inc. (1 <sup>st</sup> section) - Nagoya Stock Exchange, Inc. (1 <sup>st</sup> section) - Securities Membership Corporation Sapporo Securities Exchange - Securities Membership Corporation Fukuoka Stock Exchange

2. Position of listed company within the corporate group centering on the parent company and other relationships between listed company and the parent company.

- 1) While "Kirin Group" (the corporate group of Kirin Holdings Company, Limited ("Kirin Holdings")) aims at becoming a global leader in CSV, creating value across our world of Food & Beverages to Pharmaceuticals, Kyowa Kirin is the only company in charge of the Pharmaceuticals domain, which is a core business of Kirin Group.

Regarding personnel relationships, as of March 31, 2022, one Director of the Board, Senior Executive Officer of Kirin Holdings is appointed as a non-executive Director of Kyowa Kirin's Board with the aim of strengthening Kyowa Kirin's management structure and other initiatives, and one full-time Audit & Supervisory Board Member at Kirin Holdings also serves as a part-time Audit & Supervisory Board Member of Kyowa Kirin.

- 2) Constraints, risks and benefits from a business standpoint due to membership in the corporate group centering on the parent company, as well as impacts on management or business activities such as those affected by transactional, personnel and capital relationships, etc. with the parent company and its corporate group.

While the Company aims at realizing 'the creation a of life-changing value', we consider that management resources owned by Kirin Holdings and its Group companies are useful for our Company and our Group companies. Kirin Group's knowledge and know-how in the domains of production management and engineering contribute to building our business foundation.

In order to fulfill its social responsibility in the future, the Company will further utilize Kirin Group's knowledge and know-how in the domains of environmental conservation and stable supply of pharmaceutical products. In addition, in order to 'meet healthcare needs of the society across the entire patient care pathway', we consider that opportunities to solve issues facing people confronted with diseases exist at the intersection with Health Science domain, which Kirin Holdings focuses on.

As a core company operating an ethical pharmaceuticals business in the Kirin Holdings corporate group, Kyowa Kirin maintains management independence and considers itself to be unconstrained from a business standpoint and its management or business activities to be unaffected by transactional, personnel and capital relationships, etc. with the parent company and its corporate group.

- 3) Measures to ensure a certain degree of independence from the parent company

In the Integration Agreement dated October 22, 2007, it was agreed by both companies that while observing core group management policies, the Company operates as an autonomous company with independence and flexibility, ensures management independence as a listed company, strives to maximize value for all shareholders and achieves consistent growth of its corporate value. Both companies follow through the Agreement.

To ensure the effectiveness of objective management supervision and from the perspective of protecting minority shareholders, five of the nine appointed Directors of the Board and two of the five appointed Audit & Supervisory Board Members as of March 31, 2022, who do not have a conflict of interest with general shareholders, are independent outside officers, and the position of Board Chair is assumed by Mr. Akira Morita, who is an independent Director.

Kyowa Kirin establishes the Nomination & Remuneration Consultative Committee, which consists of a majority of outside officers, and is chaired by an independent Director and also conducts the evaluation on the effectiveness of the Board of Directors utilizing external advisors.

Kyowa Kirin's transactional relationships with Kirin Holdings and its group companies do include the lending of funds. In accordance with our investment policy, interest rates on the loans are determined through rational decisions, considering market interest rates for the loan period.

### 3. Transactions with controlling shareholders and other items

Fiscal year ended December 31, 2021

(million yen)

Category	Name	Transactions	Transaction amount	Account	Outstanding balance at fiscal year-end
Parent company	Kirin Holdings Company, Limited	Lending of funds *	271,812	Cash and cash equivalents	313,026

(Note) Transaction amount is the average balance through the period. Also, in accordance with our investment policy, interest rates on the loans are determined through rational decisions, considering market interest rates for the loan period.

### 4. Implementation of measures to protect minority shareholders in transactions, etc. with controlling shareholders

Transactions with the controlling shareholder, whether those be of goods and services provided by Kyowa Kirin or to Kyowa Kirin, are based on objective market information and other data, and as with ordinary transactions, rational terms are agreed, and the transaction is conducted appropriately.

In case of conducting a transaction with Kirin Holdings, the controlling shareholder, in order to address risks of conflicts of interest, when making a decision at the Board of Directors, officers who also work for the controlling shareholder, Kirin Holdings, do not participate in deliberation and resolution of such an agenda, and do not participate in our discussion and negotiations with Kirin Holdings.

With respect to a significant transaction, etc. among transactions with Kirin Holdings, in case the Company's Board does not have a majority of independent directors, the Company establishes the Supervisory Committee for Conflict of Interests in Transactions between Group Companies comprising independent directors, which serves as an advisory body to the Board of Directors and deliberates/considers the matter, for the purposes of securing the fairness and rationality of such a transaction and contributing to an improvement of the corporate value of the Company and the protection of interest of its minority shareholders.

End